Physician profile
Hina Doshi
NPI 1508857715
$1,311.59
in general payments reported to CMS, 2019-2025
16 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $16.13 · 2021: $126 · 2022: $241 · 2023: $207 · 2024: $251 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $372.86 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $151.33 | 2021-2024 | |
| Terumo Medical Corporation | $143.30 | 2025 | Navicross, Glidewire |
| Amgen INC. | $125.70 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $124.74 | 2024 | Mounjaro |
| Medtronic Vascular, INC. | $76.79 | 2019 | |
| Glaxosmithkline, LLC. | $51.65 | 2019-2025 | Nucala, Trelegy Ellipta |
| Abbott Laboratories | $46.69 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $44.53 | 2019-2025 | Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $33.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.94 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.96 | 2024 | Eohilia |
| Vanda Pharmaceuticals INC. | $29.43 | 2021 | |
| Abbvie INC. | $21.38 | 2023 | Vraylar |
| Eisai INC. | $16.06 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hina Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.